BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16978200)

  • 1. Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes.
    Baker K; Chong G; Foulkes WD; Jass JR
    Histopathology; 2006 Oct; 49(4):371-80. PubMed ID: 16978200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway.
    Baker K; Zlobec I; Tornillo L; Terracciano L; Jass JR; Lugli A
    Eur J Cancer; 2007 Feb; 43(3):624-31. PubMed ID: 17223543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
    Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
    Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
    Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Smad4 and TGF-beta2 in colorectal carcinoma.
    Kouvidou Ch; Latoufis C; Lianou E; Kouvatseas G; Kakouri E; Anagnostakis D; Vrettou-Aravani V; Betsi E; Karatapanis S
    Anticancer Res; 2006; 26(4B):2901-7. PubMed ID: 16886611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
    Sakaguchi J; Kyo S; Kanaya T; Maida Y; Hashimoto M; Nakamura M; Yamada K; Inoue M
    Gynecol Oncol; 2005 Sep; 98(3):427-33. PubMed ID: 15993480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of TGF-beta1, TbetaRII and Smad4 in colorectal carcinoma.
    Xu WQ; Jiang XC; Zheng L; Yu YY; Tang JM
    Exp Mol Pathol; 2007 Jun; 82(3):284-91. PubMed ID: 17289018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
    Kiyono K; Suzuki HI; Morishita Y; Komuro A; Iwata C; Yashiro M; Hirakawa K; Kano MR; Miyazono K
    Cancer Sci; 2009 Oct; 100(10):1809-16. PubMed ID: 19594546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMAD4/DPC4 expression and prognosis in human colorectal cancer.
    Isaksson-Mettävainio M; Palmqvist R; Forssell J; Stenling R; Oberg A
    Anticancer Res; 2006; 26(1B):507-10. PubMed ID: 16739311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and mutation of SMAD4 in poorly differentiated carcinoma and signet-ring cell carcinoma of the colorectum.
    Seshimo I; Yamamoto H; Mishima H; Kurata A; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Fukushima T; Tsujinaka T; Sekimoto M; Kikkawa N; Takenoshita S; Monden M
    J Exp Clin Cancer Res; 2006 Sep; 25(3):433-42. PubMed ID: 17167985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
    Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer.
    Zlobec I; Lugli A; Baker K; Roth S; Minoo P; Hayashi S; Terracciano L; Jass JR
    J Pathol; 2007 Jul; 212(3):260-8. PubMed ID: 17516584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells.
    Ali NA; McKay MJ; Molloy MP
    Mol Biosyst; 2010 Nov; 6(11):2332-8. PubMed ID: 20862427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma.
    Guo H; Zhang HY; Wang SL; Ye L; Yang GH; Bu H
    Chin Med J (Engl); 2007 Mar; 120(6):515-21. PubMed ID: 17439748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RING finger protein11 binds to Smad4 and enhances Smad4-dependant TGF-beta signalling.
    Azmi PB; Seth AK
    Anticancer Res; 2009 Jun; 29(6):2253-63. PubMed ID: 19528490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of BMP7 in human colorectal cancer.
    Motoyama K; Tanaka F; Kosaka Y; Mimori K; Uetake H; Inoue H; Sugihara K; Mori M
    Ann Surg Oncol; 2008 May; 15(5):1530-7. PubMed ID: 18259822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas.
    Le Gouvello S; Bastuji-Garin S; Aloulou N; Mansour H; Chaumette MT; Berrehar F; Seikour A; Charachon A; Karoui M; Leroy K; Farcet JP; Sobhani I
    Gut; 2008 Jun; 57(6):772-9. PubMed ID: 17965063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers.
    Kodach LL; Wiercinska E; de Miranda NF; Bleuming SA; Musler AR; Peppelenbosch MP; Dekker E; van den Brink GR; van Noesel CJ; Morreau H; Hommes DW; Ten Dijke P; Offerhaus GJ; Hardwick JC
    Gastroenterology; 2008 May; 134(5):1332-41. PubMed ID: 18471510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
    Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
    Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.